Perioperative Cardiac Damage in Vascular Surgery Patients  by Flu, W.-J. et al.
Eur J Vasc Endovasc Surg (2010) 40, 1e8REVIEW
Perioperative Cardiac Damage in Vascular
Surgery PatientsW.-J. Flu a, O. Schouten b, J.-P. van Kuijk a, D. Poldermans c,*a Department of Anesthesiology, Erasmus Medical Center, ‘s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
b Department of Surgery, Reinier de Graaf Hospital, Delft, The Netherlands
c Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
Submitted 26 November 2009; accepted 11 March 2010
Available online 18 April 2010KEYWORDS
Asymptomatic
myocardial damage;
Vascular surgery* Corresponding author. Tel.: þ31 10
E-mail address: d.poldermans@era
1078-5884/$36 ª 2010 European Socie
doi:10.1016/j.ejvs.2010.03.014Abstract Background: Patients undergoing vascular surgery are at increased risk for devel-
oping cardiac complications. Majority of patients with perioperative myocardial damage are
asymptomatic. Our objective is to review the available literature addressing the prevalence
and prognostic implications of perioperative myocardial damage in vascular surgery patients.
Methods: An Internet-based literature search was performed using MEDLINE to identify all pub-
lished reports on perioperative myocardial damage in vascular surgery patients. Only those
studies published from 2000 to 2010 evaluating myocardial damage using troponin I or T, with
or without symptoms of angina pectoris were included.
Results: Thirteen studies evaluating the prevalence of perioperative myocardial ischaemia or
infarction were included in the study. The incidence of perioperative myocardial ischaemia
ranged from 14% to 47% and the incidence of perioperative myocardial infarction ranged from
1% to 26%. In addition, 10 studies evaluating the prognostic value of perioperative myocardial
ischaemia towards postoperative mortality or the occurrence of major adverse cardiac events
were included. In the retrieved studies, hazard ratios varied from 1.9 to 9.0.
Conclusion: The high prevalence and asymptomatic nature of perioperative myocardial
damage, combined with a substantial influence on postoperative mortality of vascular surgery
patients, underline the importance of early detection and adequate management of perio-
perative myocardial damage.
This article provides an extended overview regarding the prevalence and prognostic value of
perioperative myocardial ischaemia and infarction in vascular surgery patients. In addition,
treatment options to reduce the risk of perioperative myocardial damage are provided based
on the current available literature.
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with a concomitant reduction of coronary perfusion,
9In the present article, an extended overview is provided
regarding the prevalence and prognostic value of peri-
operative myocardial ischemia and infarction in vascular
surgery patients. In addition, treatment options in order to
reduce the risk of perioperative myocardial damage are
provided based on the current available literature.Perioperative myocardial damage: ischaemia
and infarction
The heart is an organ with a high metabolic demand, even at
rest, and requires a continuous high level of oxygen supply to
the myocardium. The amount of oxygen supplied to the
myocardium is determined by (1) the blood flow in the
coronary arteries and (2) the oxygen-carrying capacity of the
blood. Therefore, an increase of myocardial oxygen demand
must be met by an increase in coronary blood flow. In addi-
tion, an imbalance between oxygen supply and oxygen
demand results in myocardial damage, characterised by
myocardial ischaemia and myocardial infarction (MI).1
In general, myocardial damage can be subdivided
according to two pathological processes, described as type
1 and 2 by the universal definition of MI.2 Type 1 MI is
defined as an acute coronary syndrome that occurs when
a coronary plaque ruptures, leading to thrombus formation,
acute coronary thrombosis, supply ischaemia and MI. A
reduction of arterial blood flow is the cause of myocardial
damage in type 1 MI. In addition, myocardial damage may
also be caused by a sustained myocardial oxygen supplye
demand imbalance, or type 2 MI. In case of type 2 MI,
myocardial damage is caused by an increased myocardial
oxygen demand in response to stress, characterised by
tachycardia and increased myocardial contractility, which
is not met by a sufficient increase of coronary blood flow.3
During surgery, high catecholamine production is
responsible for vasoconstriction and haemodynamic stress,4
associated with an increased oxygen demand of the
myocardium. Perioperative myocardial damage may occur
when the increased oxygen demand is not met by an
adequate increase of oxygen supply.5 This is similar to MIs
occurring in the non-surgical setting; however, surgery
itself is a significant stress factor leading to an increased
risk of plaque rupture. Two retrospective studies investi-
gated the coronary pathology of fatal perioperative MI. As
demonstrated in the autopsy study by Dawood et al., 55% of
the fatal perioperative MIs have direct evidence of plaque
disruption, defined as fissure or rupture of plaque and
haemorrhages into the plaque cavity.6 Similar autopsy
results were found in the study of Cohen and Aretz, who
observed that plaque rupture was present in 46% of patients
with postoperative MI.7
Next to surgical stress, haemodynamic fluctuations
during surgery are an important cause of perioperative
myocardial damage as well. Perioperative fluid adminis-
tration increases the pre- and afterload in the left
ventricle, making patients susceptible to perioperative
myocardial damage.8 Conversely, perioperative preload
reductions in the left ventricle can result in tachycardialeading to perioperative myocardial damage.
It is estimated that of the 230 million patients under-
going major surgery annually, approximately 1% (2,300,000
patients) suffer perioperative MI with a cardiovascular
mortality rate around 0.3% (690.000 patients).10 However,
cardiac risk imbedded in surgical interventions can differ
depending on the magnitude, duration, location, blood loss
and fluid shifts related to the specific procedure. In 2005,
Boersma et al. developed a model to risk stratify surgical
procedures, based on the occurrence of 30-day cardiac
death and MI.11 Surgical procedures were classified low
cardiac risk (<1%), intermediate cardiac risk (1e5%) or high
cardiac risk (>5%) for the development of 30-day adverse
cardiac outcome. High-cardiac-risk surgery is considered to
be open lower extremity revascularisation and open
abdominal aortic surgery. In addition, percutaneous trans-
luminal angioplasty, endovascular aortic aneurysm repair
and carotid surgery are considered as intermediate cardiac
risk because they are associated with reduced myocardial
stress and the need for lower fluid administration compared
with open lower extremity revascularisation and open
abdominal aortic surgery.12,13Methods
A systematic Medline search was undertaken to identify
studies addressing perioperative cardiac damage, assessed
with troponin I or T, in patients undergoing elective
peripheral vascular surgery published between 2000 and
2010. The keywords used were ‘cardiac troponin, vascular
surgery’, ‘perioperative ischaemia, vascular surgery’,
‘cardiac ischaemia, vascular surgery’ in combination with
‘prevalence’, ‘incidence’, ‘prognostic value’, ‘long term
outcome’, ‘long-term mortality’ and ‘major adverse
cardiac events’. The retrieved articles were also searched
for any relevant references. The current study included
solely studies addressing the prognostic value of increased
troponin T or I levels when using regression analyses or
contingency table analyses.Results
Vascular surgery patients are at increased risk for devel-
oping perioperative cardiac complications, especially
patients undergoing open lower extremity revascularisation
and open abdominal aortic surgery. In 1981, Brown et al.
described that about 40% of the patients undergoing elec-
tive abdominal aortic aneurysm resection had a history of
either MI or angina pectoris.14 In addition, Hertzer et al.
performed routine coronary angiography in more than 1000
patients to detect uncorrected coronary artery disease in
patients with advanced peripheral vascular disease.15 They
found coronary artery disease to be highly present in these
patients with a prevalence of severe three-vessel disease in
18% of the patients and left main disease in 4% of
patients.15 In 1989, Oeyang et al. observed that episodes of
perioperative myocardial damage in patients having
peripheral vascular surgery are most often silent.16 Utoh
et al. performed routine coronary angiography in patients
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that the incidence of silent ischaemia was 20%. In addition,
the authors concluded that the number of coronary risk
factors and resting electrocardiograms were not worth-
while for predicting silent coronary artery disease.17
Perioperative myocardial damage is difficult to diagnose
due to its silent nature. In 1994, Adams 3rd et al. demon-
strated that the measurement of cardiac troponin I is
a sensitive and specific method for the diagnosis of peri-
operative MI in vascular surgery patients.18 Hereafter,
several studies have correlated serial cardiac troponin
measurements with continuous 12-lead ST-segment analysis
after major vascular surgery.19 Troponin elevations occurred
after prolonged, transient, postoperative ST-segment
depression, and peak troponin elevations correlated with
the duration of ST depression.20 Landesberg et al. demon-
strated that 85%ofpostoperative cardiac complicationswere
preceded by prolonged ST-segment depression.21 In addi-
tion, Fleisher et al. found that 78% of patients with cardiac
complications had at least one episode of prolonged
myocardial ischaemia (¡.e.,>30min) either before or during
the cardiac event.22 The hypothesis that ST-depression can
lead to perioperative MI is further supported by increased
troponin T levels during or shortly after prolonged
ST-depression ischaemia.23 Episodes of perioperative
ST-depression, indicating endocardial (non-transmural)
myocardial ischaemia, has been described in up to 41% of
vascular surgery patients and mostly occur within the first 2
days after surgery.24 ST-elevation-type ischaemia is consid-
ered relatively uncommon, confirmed by the incidence (12%)
of intra-operative ST-elevation in a study performed by
London et al.25 Recent studies using highly sensitive troponin
essays demonstrated that low-level (>0.03 ngml1) troponin
elevations postoperatively are common in high-cardiac-risk
patients, even with little or no evidence of ischaemia with
electrocardiogram monitoring.26
In the current study, we performed a systematic Medline
search to evaluate the prevalence of myocardial ischaemia
or infarction in vascular surgery patients detected with
troponin I or T measurement whether or not in combination
with electrocardiogram changes or symptoms of angina
pectoris. As demonstrated in Table 1, the incidence of
perioperative myocardial ischaemia ranged from 14% to 47%
and that of perioperative MI ranged from 1% to 26%. The
wide range of incidence might be related to (1) different
cut-off values of troponin I or T used in the study, (2)
a variety of vascular procedures included in the studies and
(3) that patient-specific cardiac risk factors differed
between the studies. For example, in the study performed
by Ali et al. the highest incidence of perioperative
myocardial damage was found (both ischaemia and infarc-
tion), probably related to the fact that this study only
included patients undergoing open abdominal aortic repair.
In addition, Schouten et al. included only included patients
with three or more cardiac risk factors (age >70 years,
angina pectoris, MI, congestive heart failure, stroke, renal
dysfunction and diabetes mellitus). In the study performed
by Abraham et al., about 75% of the patients underwent
endovascular abdominal aortic aneurysm repair and
patients with increased cardiac troponin T in combination
with a significant postoperative increase in serum creati-
nine (>50%) were excluded from the study. Importantly,Abraham et al. report the highest incidence of perioper-
ative myocardial damage within the first 3 days after
surgery.27Prognosis after perioperative myocardial damage
In order to put the significance of perioperative myocardial
damage into perspective, it is pivotal to address the influ-
ence of perioperative myocardial damage on long-term
postoperative outcome. Multiple studies have been per-
formed over the years to evaluate this issue. In 1982,
Jamieson et al. were among the first to describe the
influence of ischaemic heart disease on early and late
mortality after surgery for peripheral occlusive vascular
disease. The authors concluded that coronary artery
disease is a major determinant of both early and late
mortality after arterial reconstruction and that selective
myocardial revascularisation may improve survival of these
patients.28 Because perioperative myocardial damage is
most often silent, the great majority of patients (95%) with
perioperative myocardial damage remain untreated. This
might contribute to an increased risk of long-term cardio-
vascular mortality as well.16,29,30
From 2000 to 2010, perioperative myocardial damage,
defined as postoperative troponin elevations whether or
not in combination with ST-segment alterations, has been
related to adverse short-, mid- and long-term cardiac
morbidity and mortality as well in multiple studies, out-
lined in Table 2.20,27,31e38 In the current study, hazard
ratios describing the prognostic value of troponin T or I
towards postoperative mortality or the occurrence of major
adverse cardiac events varied from 1.9 to 9.0.
In patients undergoing vascular surgery, asymptomatic
elevated troponin T levels were associated with an
increased risk, of more than four- to six-fold, for cardiac
events during a 6-month follow-up period, as demonstrated
by Kim et al.39 Landesberg et al. and Kertai et al. studied
the prognostic value of low- and intermediate-to-high cut-
off levels of troponin T elevations on long-term mortality
after vascular surgery. These studies demonstrated that
postoperative troponin elevations even at low cut-off levels
are independent and complementary predictors of long-
term mortality.20,37 In addition, early mortality after peri-
operative MI ranges between 3.5% and 25% and is higher in
patients with an intermediate- to high-level troponin
elevation, compared with patients with a low-level
troponin elevation.20,32,34.
Endovascular surgery is associated with a reduced inci-
dence of perioperative myocardial damage, compared with
open vascular surgery, possibly explained by reduced
myocardial stress during endovascular procedures.13
However, Winkel et al. recently demonstrated that
asymptomatic perioperative myocardial damage, defined
as cardiac troponin T elevations in the absence of ischaemic
symptoms or electrocardiogram abnormalities, was associ-
ated with an increased mortality risk of patients undergoing
endovascular abdominal aortic aneurysm repair.40 During
a 2.9-year follow-up of 220 patients, they found that
patients with asymptomatic myocardial damage had
a mortality rate of 49%, compared with 15% for patients
without perioperative myocardial damage (P < 0.001).
Table 1 Prevalence of perioperative myocardial ischaemia or MI in vascular surgery patients.
Study Surgical
procedure
N Myocardial
ischaemia
Myocardial
infarction
Bollinger et al.53
(2009)
AAA
Lower extremity
133 cTnI >2.0 14% e
Flu et al.54
(2009)
AAA
Carotid
627 cTn-T >0.03 17% cTn-T >0.2 þ symptoms or
ECG changes
5%
Ali et al. 33 *
(2008)
AAA 43 cTnI >0.54 47% cTnI >0.54 þ symptoms or
ECG changes
26%
McFalls et al.55 AAA
Lower extremity
377 cTnI >0.1 27% cTnI >0.1 þ symptoms or
ECG changes
10%
Schouten et al.56 **
(2007)
AAA 77 cTn-T >0.03 30% cTn-T >0.2 þ symptoms or
ECG changes
7%
Barbagallo et al.34
(2006)
AAA
Lower extremity
75 cTnI >0.5 33% cTn-T >0.05 þ symptoms or
ECG changes
12%
Abraham et al.27 ***
(2005)
AAA 149 cTn-T >0.02 11% [ cTn-T þ ECG changes 1%
Manach et al.35
(2005)
AAA 1136 cTnI >0.2 14% cTnI >1.5 5%
Landesberg et al.20
(2003)
AAA
Lower extremity/
carotid
503 cTnI >0.6 or
cTn-T >0.03
23% [ cTnI or [ cTn-T þ
Symptoms
11%
Kim et al.39 *
(2002)
AAA
Lower extremity
229 cTnI >0.4 43% [ cTnI þ ECG changes 3%
Haggart et al.57
(2001)
AAA
Lower extremity
35 cTnI >0.5 29% cTnI >0.5 þ symptoms or
ECG changes
14%
Andrews et al.36
(2001)
AAA
Lower extremity/carotid
100 cTnI >0.8 18% [ CKMB þ Symptoms or
ECG changes
12%
Godet et al.58
(2000)
AAA 316 cTnI >0.5 16% cTnI >1.5 8%
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Prevention of perioperative myocardial damage
In general, the management of perioperative myocardial
damage is focussed on (i) coronary plaque stabilisation to
reduce acute coronary syndromes, with subsequent supply
ischaemia (type I MI), that occurs when a coronary plaque
ruptures and (2) limiting surgical stress, which is the cause
of sustained myocardial oxygen supplyedemand imbalance
(type 2 MI). The high incidence of perioperative myocardial
damage reflects the high prevalence of underlying ischae-
mic heart disease in the vascular surgery population.29
Therefore, adequate preoperative evaluation is inevitable
to: (1) identify patients at increased cardiac risk, (2)
initiate risk reduction therapy and (3) select optimal
surgical and anaesthesia techniques. In conventional
preoperative cardiac risk indices (Revised Cardiac Risk
index and Adapted Lee index), age, heart failure, ischaemic
heart disease, cerebrovascular disease, renal dysfunction,
diabetes mellitus and high-risk surgery (such as vascular
surgery) have been identified as independent predictors of
perioperative cardiovascular events.11,30
Pharmacological treatment
The unpredictable progression of an unstable coronary
plaque during surgical stress is the most important target
for systemic pharmacological therapy to reduce the inci-
dence of perioperative myocardial damage.b-Blockers
In the non-surgical setting, b-blockers are widely used for
the prevention and treatment of ischaemic heart disease
and heart failure, all major determinants of adverse post-
operative outcome Proposed mechanisms by which
b-blockers exert intra-operative cardioprotective effects
include heart rate control, reduction of systolic pressure
and ventricular contractile force and its anti-arrhythmic
properties. In the long term, b-blockers reduce mechanical
stress imposed on coronary plaques preventing plaque
rupture.37 In addition, the anti-inflammatory properties of
b-blockers exert a beneficial effect towards coronary pla-
que stabilisation as well.38 In addition, b-blockers are
known to reduce the process of adverse cardiac remodel-
ling in patients with impaired left ventricular function,
which is highly prevalent in the vascular surgery population,
by inhibiting the sympathetic nervous system and hormone
activation (A-type and B-type natriuretic peptides and
norepinephrine).41
In the most recent European Society of Cardiology (ESC)
guidelines, b-blockers are recommended (Class I, Level of
evidence B) in patients scheduled for high-risk surgery. In
addition, b-blockers should be considered (Class IIa, level
of evidence B) in patients undergoing intermediate-risk
surgery, such as percutaneous transluminal angioplasty,
endovascular aortic aneurysm repair and carotid surgery.42
Factors that influence the effectiveness of perioperative
b-blockers treatment are the patients with underlying
Table 2 Prognostic value of increased perioperative troponin T or I levels for cardiac outcome of vascular surgery patients.
Study Surgical procedure N Troponin I or T Cardiac outome
Bollinger et al.53
(2009)
AAA
Lower extremity
133 cTnI >2.0 MACE 1 year:
Mortality 1 year:
HR 9.0 (3.6e23.2)
HR 8.5 (2.9e24.9)
Winkel et al40
(2009)
AAA 220 cTn-T >0.01 Mortality LT HR 2.3 (1.1e5.1)
Ali et al. 33*
(2008)
AAA 43 cTnI >0.54 MACE LT OR 5.4 (1.2e24)
McFalls et al.55
(2008)
AAA
Lower extremity
377 cTnI >0.1 Mortality 1 year P < 0.01*
Barbagallo et al.34
(2006)
AAA
Lower extremity
75 cTnI >0.5 MACE 1 month P < 0.003*
Manach et al.35
(2005)
AAA 1136 cTnI >0.2 In-hospital mortality P < 0.05
Kertai et al.59
(2004)
AAA
Lower extremity
393 cTn-T >0.1 Mortality LT HR 1.9 (1.1e3.1)
Landesberg et al.20
(2003)
AAA
Lower extremity/
carotid
447 cTnI >0.6 or
cTn-T >0.03
Mortality LT OR 2.2 (1.48e3.42)
Kim et al.39 *
(2002)
AAA
Lower extremity
229 cTnI >0.4 Mortality 6 m OR 4.9 (1.3e19)
Andrews et al.36
(2001)
AAA
Lower extremity/carotid
100 cTnI >0.8 In-hospital MACE P < 0.001
* Contingency table analyses evaluating increased risk for adverse cardiac outcome associated with perioperative increases of troponin T.
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such as b-blocker type, b-blocker dose and timing of
b-blocker initiation before surgery. As recommended in the
ESC guidelines, b-blocker treatment should be initiated
optimally between 30 days and at least 1 week before
surgery with a target heart rate between 60 and 70 beats
per minute and systolic blood pressure >100 mmHG.
Statins
Statins are widely used to decrease low-density lipoprotein
cholesterol in patients. Furthermore, statins seem to sta-
bilise atherosclerotic plaques during surgery through
pleiotropic effects and therefore have a beneficial influ-
ence on cardiovascular outcome.43 Multiple studies have
not only shown beneficial effects of statins in patients with
coronary artery disease, but in patients undergoing vascular
surgery as well.44e46 In the most recent ESC guidelines,
initiation of statins is recommended in patients undergoing
high-risk surgery, optimally between 30 days and at least 1
week before surgery (Class I, Level of evidence B).42
Anti-platelet agents
The perioperative surgical stress results in a hypercoagu-
lable state, which is in combination with atherosclerotic
plaques, the perfect substrate for the development of
perioperative cardiac damage. Anti-platelet drugs are
established agents in the prevention of cardiovascular and
cerebrovascular ischaemic events. Treatment with aspirin
or clopidogrel is recommended in patients with stable
coronary artery disease to prevent cardiovascular events.47
Aspirin irreversibly blocks platelet cyclo-oxygenase-1
known to decrease the tromboxane-A2 synthesis. There-
fore aspirin reduces platelet activation andvasoconstriction.48 Aspirin reduces the risk of non-fatal MI
by 34% and, in the setting of secondary prevention, reduces
cardiovascular events by 27% and cardiovascular deaths by
18%.49 The most recent ESC guidelines addressing peri-
operative care state that continuation of aspirin should be
considered in the perioperative period of patients previ-
ously treated with aspirin (Class IIa, level of evidence B).42
The thienopyridine derivate clopidogrel is an anti-platelet
agent that inhibits the adenosine diphosphate-mediated
platelet aggregation.50 Randomised controlled studies are
needed to investigate the role of clopidogrel as a preven-
tive treatment in patients with asymptomatic cardiac
damage.
Prophylactic revascularisation
Preoperative cardiac risk evaluation by means of risk factor
assessment and non-invasive testing may identify vascular
surgery patients with asymptomatic coronary artery
disease. Two randomised, controlled trials have evaluated
the potential benefit that may be expected from preoper-
ative revascularisation in these patients. The Coronary
Artery Revascularisation Prophylaxis (CARP) trial rando-
mised 510 patients with significant coronary artery stenosis
to receive either revascularisation or no revascularisation
prior to vascular surgery.51 The main finding of the CARP
trial was that there was no difference in the primary
outcome of long-term mortality (median follow-up 2.7
years) in patients who underwent preoperative coronary
revascularisation compared with patients who received
optimised medical therapy (22% vs. 23%, relative risk: 0.98;
95% CI: 0.70e1.37). In the prospectively randomised
DECREASE-V trial,52 mainly including patients with three-
vessel coronary artery disease, comparable results to the
CARP trial were obtained. Although the study population in
the DECREASE-V trial reflected vascular surgery patients at
6 W.-J. Flu et al.highest cardiac risk, revascularisation did not improve
cardiovascular outcomes. The incidence of the composite
endpoint of 30-day cardiovascular mortality and MI was 43%
versus 33% (odds ratio (OR) 1.4, 95% CI: 0.7e2.8).
Furthermore, no benefit was observed during 1-year follow-
up after coronary revascularisation (49 vs. 44%; OR 1.2, 95%
CI: 0.7e2.3; P Z 0.48). The results from these trials indi-
cate that prophylactic coronary revascularisation of
cardiac-stable patients provides no benefit for post-
operative outcome, with an exception for patients with left
main coronary artery stenosis. The reasoning behind this
apparent lack of benefit could be related to the fact that
perioperative myocardial damage is not only caused by
a significant blood-flow-limiting coronary artery stenosis
(Type 1 MI). The perioperative stress response (evoking
type 2 MI) may cause non-flow-limiting coronary plaques to
rupture during surgery and to become flow limiting after
all. This may explain why surgical or percutaneous treat-
ment of flow-limiting coronary plaques apparently provides
insufficient extra protection in addition to pharmacological
treatment. In the most recent ESC guidelines addressing
perioperative care, it is only recommended to consider
prophylactic revascularisation in patients undergoing high-
risk surgery, such as lower extremity revascularisation or
open abdominal aortic surgery, with proven ischaemic
heart disease (Class IIb, level of evidence B).42
Future perspective: is there a role for remote ischemic
preconditioning?
Because prophylactic coronary revascularization had not
proven to be successful, there remains a need for alter-
native strategies to protect the myocardium during vascular
surgery. Research performed by Przyklenk et al. in a canine
heart models demonstrated that brief occlusions of a coro-
nary artery may protect the myocardial bed supplied by
that coronary artery from prolonged ischemia.56 In addi-
tion, Gho et al. demonstrated that brief ischemia in
‘‘remote’’ organs (i.e. after occlusion of the anterior
mesenteric artery or left renal artery) protects the
myocardium against infarction as effectively as myocardial
preconditioning, described by Przyklenk et al.57 Therefore,
brief ischemia followed by reperfusion in one organ may
provide systemic protection from prolonged ischemia in
another organ. In the patients undergoing abdominal
aneurysm repair remote ischemic preconditioning has been
evaluated as well. Ali et al. included eighty-two patients
which were randomized to conventional abdominal aortic
aneurysm repair (control) and abdominal aortic aneurysm
repair with remote ischemic preconditioning.58 Two cycles
of intermittent cross clamping of the common iliac artery
with 10 minutes ischemia followed by 10 minutes reperfu-
sion served as the remote ischemic preconditioning stim-
ulus. The authors found that remote ischemic
preconditioning reduced the incidence of postoperative
myocardial injury, MI, and renal impairment. In addition, in
a small pilot study, Walsh et al. demonstrated that remote
ischemic preconditioning reduced urinary biomarkers of
renal injury in patients undergoing elective endovascular
abdominal aneurysm repair.59 However, the authors point
out that future large scale trials are needed to determine
the effect of remote ischemic preconditioning on the
occurrence of major adverse cardiac events.Conclusion
The high prevalence and asymptomatic nature of peri-
operative myocardial damage, combined with a substantial
influence on postoperative mortality of vascular surgery
patients, underlines the importance of early detection and
adequate management of perioperative myocardial
damage. With the use of preoperative cardiac risk indices,
high-cardiac-risk patients at risk for developing perioper-
ative myocardial damage during vascular surgery can be
unveiled. Routine assessment of perioperative cardiac
troponin levels and/or continuous electrocardiogram
monitoring can detect perioperative myocardial damage in
patients at risk. In order to reduce the risk of developing
perioperative myocardial damage, pharmacological treat-
ment with b-blockers, statins and aspirin has demonstrated
to exert beneficial effects. In addition, prophylactic coro-
nary revascularisation does not seem to provide sufficient
extra protection in addition to pharmacological treatment.
Future randomised, controlled trials are needed to eval-
uate if remote ischaemic preconditioning or treatment with
clopidogrel may serve as novel preventive treatment
strategies to reduce asymptomatic myocardial damage
during vascular surgery.
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